home / stock / bivi / bivi news

BIVI News and Press, BioVie Inc. From 05/16/23

Stock Information
Company Name: BioVie Inc.
Stock Symbol: BIVI
Market: NASDAQ
Website: biovieinc.com
Menu
BIVI BIVI Quote BIVI Short BIVI News BIVI Articles BIVI Message Board
Get BIVI Alerts

News, Short Squeeze, Breakout and More Instantly...
BIVI - BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson's Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress

CARSON CITY, Nev., May 16, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease,&...
BIVI - BioVie Inc. (NASDAQ: BIVI) is a Stock Spotlight on 5/8

BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.49% on the day to $8.2. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its prod...

BIVI - BioVie Inc. (NASDAQ: BIVI) is a Stock Spotlight on 4/25

BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved -7.09% on the day to $7.21. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its pr...

BIVI - BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting

CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...
BIVI - BioVie Inc. (NASDAQ: BIVI) is a Stock Spotlight on 4/19

BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.98% on the day to $8.25. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its pro...

BIVI - BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023

CARSON CITY, Nev., April 17, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...

BIVI - BioVie Day And The Path Of Least Resistance To Approval In Alzheimer's

2023-04-10 06:00:47 ET Summary Seven months separate BioVie investors from Phase 3 results in Alzheimer’s disease. During BioVie Day, the company announced six upcoming Phase 3 trials in Alzheimer’s, Parkinson’s, MCI and ascites. Good Phase 2 results in Pa...
BIVI - BioVie Inc. and iRemedy Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / March 24, 2023 / RedChip Companies will air new interviews with BioVie Inc. (NASDAQ:BIVI) and iRemedy on The RedChip Money Report® on Bloomberg TV, this Saturday, March 25, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes acr...

BIVI - BioVie Announces Data from Phase 2 Parkinson's Disease Trial Accepted for Presentation at AD/PD 2023

CARSON CITY, Nev., March 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...

BIVI - BioVie Day says webinar registration now open for investors

--News Direct-- BioVie CEO Cuong Do joins Proactive's Natalie Stoberman to share the details of the company's upcoming BioVie Day webinar on March 23. Do says BioVie Day will feature a comprehensive overview of the company’s programs in Alzheimer’s disease, Parkinson’...
Previous 10 Next 10